TRML
Price:
$47.98
Market Cap:
$1.23B
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Industry
Biotechnology
IPO Date
2021-05-07
Stock Exchange
NASDAQ
Ticker
TRML
According to Tourmaline Bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -13.95. This represents a change of 144.68% compared to the average of -5.70 of the last 4 quarters.
The mean historical PE Ratio of Tourmaline Bio, Inc. over the last ten years is -306571.50. The current -13.95 PE Ratio has changed -99.55% with respect to the historical average. Over the past ten years (40 quarters), TRML's PE Ratio was at its highest in in the December 2020 quarter at -4.23. The PE Ratio was at its lowest in in the March 2022 quarter at -1013352.27.
Average
-306571.50
Median
-8.78
Minimum
-1839366.70
Maximum
-2.95
Discovering the peaks and valleys of Tourmaline Bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 38.45%
Maximum Annual PE Ratio = -2.95
Minimum Annual Increase = -100.00%
Minimum Annual PE Ratio = -1839366.70
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -7.02 | 138.00% |
| 2023 | -2.95 | -71.98% |
| 2022 | -10.53 | -100.00% |
| 2021 | -1839366.70 | 38.45% |
| 2020 | -4.78 | -87.07% |
The current PE Ratio of Tourmaline Bio, Inc. (TRML) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-6.83
5-year avg
-367878.40
10-year avg
-306571.50
Tourmaline Bio, Inc.’s PE Ratio is greater than Terns Pharmaceuticals, Inc. (-27.08), less than Precigen, Inc. (-2.59), less than Immatics N.V. (-10.68), less than ORIC Pharmaceuticals, Inc. (-8.33), less than Enliven Therapeutics, Inc. (-11.13), less than Amylyx Pharmaceuticals, Inc. (-9.06), less than Relay Therapeutics, Inc. (-4.63), less than Dianthus Therapeutics, Inc. (-13.37), less than Wave Life Sciences Ltd. (-10.48), less than Syndax Pharmaceuticals, Inc. (-5.49),
| Company | PE Ratio | Market cap |
|---|---|---|
| -27.08 | $2.44B | |
| -2.59 | $1.13B | |
| -10.68 | $1.44B | |
| -8.33 | $1.11B | |
| -11.13 | $1.27B | |
| -9.06 | $1.20B | |
| -4.63 | $1.39B | |
| -13.37 | $1.62B | |
| -10.48 | $1.25B | |
| -5.49 | $1.71B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tourmaline Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tourmaline Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Tourmaline Bio, Inc.'s PE Ratio?
How is the PE Ratio calculated for Tourmaline Bio, Inc. (TRML)?
What is the highest PE Ratio for Tourmaline Bio, Inc. (TRML)?
What is the 3-year average PE Ratio for Tourmaline Bio, Inc. (TRML)?
What is the 5-year average PE Ratio for Tourmaline Bio, Inc. (TRML)?
How does the current PE Ratio for Tourmaline Bio, Inc. (TRML) compare to its historical average?